NP94023a-d Ellipta Inhalers

Concepts

• edinburgh
• pharmaceutical products
• dry powder inhaler
• d ellipta inhalers
• supply of ellipta inhalers
• supply of a range of ellipta inhalers
• ellipta
• individual framework agreements
• dose
• micrograms

Location

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014

Description

Supply of Ellipta Inhalers to NHS Scotland: NP94023a: Umeclidinium bromide 65micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler (Anoro® Ellipta®) NP94023b: Umeclidinium bromide 65micrograms/dose dry powder inhaler (Incruse® Ellipta®) NP94023c: Fluticasone furoate 184micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler (Relvar® Ellipta®) NP94023c: Fluticasone furoate 92micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler (Relvar® Ellipta®) NP94023d: Fluticasone furoate 92micrograms/dose / Umeclidinium 55micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler (Trelegy® Ellipta®)

Total Quantity or Scope

The four individual Framework Agreements are for the supply of a range of Ellipta Inhalers to NHS Scotland. Each Framework Agreement has been awarded as a single supplier framework agreement to 1 Framework Participant.

Award Detail

Award Criteria

CPV Codes

• 33600000 - Pharmaceutical products

Indicators

• Award on basis of price.

Legal Justification

The medicines awarded to the individual framework agreements are protected by exclusive rights, including intellectual property rights, in line with Regulation 33(1)(b)(iii) of the Public Contracts (Scotland) Regulations 2015.

Other Information

Total estimated value of the procurement in Sections II.1.7 and V.2.4 covers the forty-eight (48) month contract duration and the twelve (12) month extension period of the Framework Agreements. (SC Ref:743493)